Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations of the PKD1 and PKD2 genes.
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
In a Japanese study, certain men with chronic kidney disease had greater risks for 3 or more nightly voids.
Both heart failure and coronary heart disease appear to be important underlying conditions in the pathophysiology of cardiorenal syndrome, according to investigators.
Age, hypertension, hyperuricemia, and diabetes predict kidney disease in some lymphoma patients.
Early results from the phase 3 FIDELIO-DKD study also show that finerenone reduces the risk for a cardiovascular secondary endpoint in patients with diabetic kidney disease.
In the United States, CKD prevalence from 1988 to 2016 was higher among individuals with lower education and income levels, according to a new study.
Practitioners who measure only urinary protein-to-creatinine ratio may be able to use a new albumin-to-creatinine ratio estimating equation to diagnose and manage kidney disease.
Nearly a third of serious adverse drug reactions in patients with chronic kidney disease may be preventable, according to investigators.
Confusing, ambiguous, and obsolete kidney health terms lead to frustration and distress in patients and caregivers, according researchers.